ASAN FOUNDATION

A multicenter, randomized, double-blind study evaluated the antihypertensive efficacy and safety of AML plus CC versus AML monotherapy in Korean patients with uncontrolled essential hypertension. Patients underwent a 4-week AML monotherapy run-in period, followed by randomization to combination therapy or AML monotherapy for 8 weeks. The primary outcome was DBP change at week 8, with additional assessments at weeks 4, 12, and 16. Safety was monitored through adverse events. The study aimed for KMFDS approval for the AML/CC fixed-dose combination.

FDA authorizes Phase 2a trial of Progerinin, developed by PRG Science & Technology Co., Ltd., for treating Progeria, a rare rapid-aging condition. The trial, in collaboration with The Progeria Research Foundation and Boston Children’s Hospital, aims to assess Progerinin in combination with Zokinvy, the current standard treatment. Progerinin showed a potential 50% increase in lifespan in a Progeria mouse model.

EVER-132-002 study, compliant with Helsinki and ICH GCP guidelines, was approved by national authorities and ethics committees. It enrolled HR+HER2- metastatic or locally recurrent BC patients from China, Korea, and Taiwan, requiring prior chemotherapy and measurable disease. Patients were randomized 1:1 to receive SG or chemotherapy, with PFS as the primary endpoint. Secondary endpoints included OS, ORR, DoR, CBR, safety, and QoL. Assessments involved tumor measurements, safety evaluations, and QoL questionnaires. Statistical analysis included sample size calculation, HR estimation, and safety summaries. The study design details are available in the Nature Portfolio Reporting Summary.

A randomized, double-blind, placebo-controlled, non-inferiority trial in 3 Korean hospitals aims to compare ROTEM-guided TXA administration with preemptive TXA in elective cardiovascular surgery, focusing on postoperative blood loss, transfusions, and complications. The trial, registered in 2023, involves 764 patients and follows institutional protocols for perioperative management, with data managed by a CRO.

South Korean researchers found FMTs may enhance immunotherapy efficacy for GI cancer patients, with 46.2% showing benefits. Key bacterial strains like _Prevotella merdae_ improved outcomes, while _Lactobacillus salivarius_ and _Bacteroides plebeius_ had negative impacts. Challenges include efficient production and distribution for widespread adoption.

In patients with coronary drug-eluting stents undergoing non-cardiac surgery, aspirin monotherapy showed no difference in ischemic outcomes or major bleeding compared to no antiplatelet therapy. The ASSURE DES trial, involving 926 patients, found similar rates of primary outcomes and major bleeding, with a slight increase in minor bleeding in the aspirin group. The low event rate suggests a need for further research in higher-risk scenarios.

GI Innovation and MSD collaborate on a Phase 2 trial combining GI-102 and KEYTRUDA for resistant liver cancer, melanoma, and renal cell carcinoma.

GI Innovation and Merck & Co (MSD) collaborate on a Phase II trial to assess GI-102 combined with Keytruda for metastatic liver cancer, melanoma, and renal cell carcinoma. The trial, conducted in South Korea and the US, aims to provide treatment options for patients resistant to immuno-oncology treatments.